Regulatory and reimbursement reform for cellular, acellular, and matrix-like products (CAMPs)
DOI:
https://doi.org/10.63676/wjhaj519Abstract
In August 2025, a national meeting was held in Washington, D.C., gathering 32 experts from across clinical, academic, manufacturing, legal and policy sectors to address the clinical, regulatory, and economic landscape of CAMPs. This consensus document summarizes key discussions from that meeting and the panel recommendations are aimed at improving the regulatory and reimbursement environment for CAMPs in the U.S., while concurrently ensuring Medicare beneficiaries have equitable access to advanced therapies for wound healing and amputation avoidance.
References
1. Wu S, Carter M, Cole W, et al. Best practice for wound repair and regeneration use of cellular, acellular and matrix-like products (CAMPs). J Wound Care. 2023;32(Sup4b):S1-S31. https://doi.org/10.12968/jowc.2023.32.Sup4b.S1
2. Atkin L, Bućko Z, Conde Montero E, et al. Implementing TIMERS: the race against hard-to-heal wounds. J Wound Care. 2019;23(Sup3a):S1-S50. htps://doi.org/10.12968/jowc.2019.28.Sup3a.S1
3. Armstrong DG, Tettelbach WH, Chang TJ, De Jong JL, Glat PM, Hsu JH, Kelso MR, Niezgoda JA, Tucker TL, Labovitz JM. Observed impact of skin substitutes in lower extremity diabetic ulcers: lessons from the Medicare Database (2015-2018). J Wound Care. 2021;30(Sup7):S5-S16. https://doi.org/10.12968/jowc.2021.30.Sup7.S5
4. Tettelbach W, Armstrong D, Niezgoda J, Wahab N, Cole W, Tucker T, Kelso MR. The hidden costs of limiting access: clinical and economic risks of Medicare's future effective cellular, acellular and matrix-like products (CAMPs) Local Coverage Determination. J Wound Care. 2025;34(Sup5):S5-S14. https://doi.org/10.12968/jowc.2025.0120
5. Emanuel KC. When Audits Become Ambushes: The Perils of Financially Incentivized Medicare Investigations.RACmonitor. 2025. https://racmonitor.medlearn.com/when-audits-become-ambushes-the-perils-of-financially-incentivized-medicare-investigations/ (accessed 22 October 2025)
6. Tettelbach WH, Armstrong DG, Chang TJ, et al. Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment. J Wound Care. 2022;31(Sup2):S10-S31. https://doi.org/10.12968/jowc.2022.31.Sup2.S1
7. Tettelbach WH, Driver V, Oropallo A, et al. Treatment patterns and outcomes of Medicare enrolees who developed venous leg ulcers. J Wound Care. 2023;32(11):704-718. https://doi.org/10.12968/jowc.2023.32.11.704
8. Tettelbach WH, Driver V, Oropallo A, et al. Dehydrated human amnion/chorion membrane to treat venous leg ulcers: a cost-effectiveness analysis. J Wound Care. 2024;33(Sup3):S24-S38. https://doi.org/10.12968/jowc.2024.33.Sup3.S24
9. Singh S, Young A, McNaught CE. The physiology of wound healing. Surgery. 2017;35(9):473-477. https://doi.org/10.1016/j.mpsur.2017.06.004
10. Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 2003;26(6):1879-1882. https://doi.org/10.2337/diacare.26.6.1879
11. House Committee on Appropriations. Committee Approves FY26 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act. 9 Sept. 2025. https://appropriations.house.gov/news/press-releases/committee-approves-fy26-labor-health-and-human-services-education-and-related (accessed 22 October 2025)
12. Centers for Medicare & Medicaid Services. Wasteful and Inappropriate Service Reduction (WISeR) Model Overview: Fact Sheet. 2025. https://www.cms.gov/files/document/wiser-fact-sheet.pdf (accessed 22 October 2025)
Published
Issue
Section
License
Copyright (c) 2025 International Journal of Tissue Repair
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
